ReviewJournal of medical toxicology : official journal of the American College of Medical Toxicology2017
The Pharmacology and Toxicology of Third-Generation Anticonvulsant Drugs.
Review in Journal of medical toxicology : official journal of the American College of Medical Toxicology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 46 citations in OpenAlex.
- Fruits for Seizures? A Systematic Review on the Potential Anti-Convulsant Effects of Fruits and their Phytochemicals.Current neuropharmacology · 2022Pooled it
- Seizures in brain tumors: pathogenesis, risk factors and management (Review).International journal of molecular medicine · 2025Review
- The use of newer anti-seizure medicines in women with epilepsy in pregnancy: A case series.Epilepsy & behavior reports · 2025Article
- Pharmacovigilance signal detection of psychiatric adverse events induced by third-generation antiepileptic drugs in children.Frontiers in pharmacology · 2025Article
- Pharmacological strategies for preventing post-stroke seizures and epilepsy.Frontiers in neurology · 2025Review
- Development and Delphi consensus validation of the Medication-Related Fall screening and scoring tool.International journal of clinical pharmacy · 2024Article
- Differential effects of antiseizure medications on neurogenesis: Evidence from cells to animals.Heliyon · 2024Review
- Nanoparticle-based Gene Therapy for Neurodegenerative Disorders.Mini reviews in medicinal chemistry · 2024Review
- Brain Neuroplasticity after Treatment with Antiseizure: A Review.Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology · 2023Review
- Developmental Toxicity Study of DL-4-Hydroxy-4-Phenylhexanamide (DL-HEPB) in Rats.Life (Basel, Switzerland) · 2023Article
- Biodegradable nanoparticles for the treatment of epilepsy: From current advances to future challenges.Epilepsia open · 2022Review
- Drug Delivery Challenges in Brain Disorders across the Blood-Brain Barrier: Novel Methods and Future Considerations for Improved Therapy.Biomedicines · 2021Review
- The Effect of Plasma Protein Binding on the Therapeutic Monitoring of Antiseizure Medications.Pharmaceutics · 2021Review
- Liquid chromatographic methods for determination of the new antiepileptic drugs stiripentol, retigabine, rufinamide and perampanel: A comprehensive and critical review.Journal of pharmaceutical analysis · 2021Review
- Truncal Ataxia and Prolonged Coma in an Exploratory Pediatric Perampanel Ingestion.Journal of medical toxicology : official journal of the American College of Medical Toxicology · 2021Article
- Bypassing the Blood-Brain Barrier: Direct Intracranial Drug Delivery in Epilepsies.Pharmaceutics · 2020Review
- Transcriptomic and proteomic profiling of glial versus neuronal Dube3a overexpression reveals common molecular changes in gliopathic epilepsies.Neurobiology of disease · 2020Article
- Anti-seizure therapy with a long-term, implanted intra-cerebroventricular delivery system for drug-resistant epilepsy: A first-in-man study.EClinicalMedicine · 2020Article
- Design, synthesis and biological evaluation of N-substituted α-hydroxyimides and 1,2,3-oxathiazolidine-4-one-2,2-dioxides with anticonvulsant activity.Journal of enzyme inhibition and medicinal chemistry · 2019Article
- Exploring the multifaceted neuroprotective actions of Emblica officinalis (Amla): a review.Metabolic brain disease · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Epilepsy is a neurologic disorder affecting approximately 50 million people worldwide, or about 0.7% of the population [1]. Thus, the use of anticonvulsant drugs in the treatment of epilepsy is common and widespread. There are three generations of anticonvulsant drugs, categorized by the year in which they were developed and released. The aim of this review is to discuss the pharmacokinetics, drug-drug interactions, and adverse events of the third generation of anticonvulsant drugs. Where available, overdose data will be included. The pharmacokinetic properties of third-generation anticonvulsant drugs include relatively fewer drug-drug interactions, as well as several unique and life-threatening adverse events. Overdose data are limited, so thorough review of adverse events and knowledge of drug mechanism will guide expectant management of future overdose cases. Reporting of these cases as they occur will be necessary to further clarify toxicity of these drugs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.